Susanta Paul, Tathagata Roy, Anannya Bose, Debasmita Chatterjee, Victor Roy Chowdhury, Meghamouli Rana, Ashmita Das
Susanta Paul1*, Tathagata Roy1, Anannya Bose2, Debasmita Chatterjee1, Victor Roy Chowdhury1, Meghamouli Rana1, Ashmita Das3
1Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata, India.
2Seacom Pharmacy College, Sankrail, Howrah, India.
3Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Koni, Bilaspur, India.
Volume - 14,
Issue - 3,
Year - 2021
Liposomes are the sphere-shaped vesicles consisting of one or more phospholipid bilayers. Structurally the liposomal vesicles are the bilayered vesicles that consist of a core of aqueous solution and a lipid spheres that contain no aqueous material. They are generally made up of phospholipids. Liposomal drug delivery systems have been widely used in pulmonary drug delivery for multiple applications which includes optimum solubilization of active pharmaceutical agents, prolonged period of drug release. Moreover, the site avoidance and site-specific drug targeting therapy could be achieved by the liposomal drug delivery system, to inhibit the tissue toxicity of many potent drug substances. In this present review, formulation aspects of liposomes, various aerosolization methods and the characterization methods of liposome formulation and an extensive overview of the use of liposomes as a pulmonary drug delivery system for the treatment of diseases like tuberculosis and lung cancer and are discussed. Liposomes can be used as a successful drug carrier in the fields like lung infection, tumor targeting, genetic transfer, immunomodulation, skin, and topical therapy.
Cite this article:
Susanta Paul, Tathagata Roy, Anannya Bose, Debasmita Chatterjee, Victor Roy Chowdhury, Meghamouli Rana, Ashmita Das. Liposome Mediated Pulmonary Drug Delivery System: An updated Review. Research J. Pharm. and Tech 2021; 14(3):1791-1796. doi: 10.5958/0974-360X.2021.00318.8
1. Bakowsky H, Richter T, et al. Adhesion characteristics and stability assessment of lectin-modified liposomes for site-specific drug delivery. Biochim Biophys Acta. 2008; 1778: 242–249.
2. Gaspar MM, Bakowsky U, Ehrhardt C. Inhaled liposomes- current strategies and future challenges. J Biomed Nanotechnology. 2008; 4: 245–257.
3. Bangham AD, Horne RW, et al. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron Microscope. J Mol Biol. 1964; 8: 660-668.
4. Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett. 2005; 10: 711-719.
5. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/ niosomal delivery systems for anti-psoriatic drug dithranol. Int J Pharm. 2001; 228(1-2): 43-52.
6. Hamilton RL, Goerke J, Guo L. Unilamellar liposomes made with the French pressure cell: A simple preparative and semi-quantitative technique. J Lipid Res. 1980; 21: 981-992.
7. Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta. 2007; 1768: 1121–1127.
8. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997; 154: 123-140.
9. Andresen TL, Davidsen J, Begtrup M, Mouritsen OG, Jørgensen K. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J. Med. Chem. 2004; 47: 1694–1703.
10. Antohe F, Lin L, Kao GY, Poznansky MJ, Allen TM. Transendothelial movement of liposomes in vitro mediated by cancer cells, neutrophils or histamine. J. Liposome Res. 2004; 14: 1–25.
11. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int. J. Nanomedicine. 2015; 10: 975–999.
12. Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond). 2013; 8: 1509–1528.
13. Ding BS, Dziubla T, Shuvaev VV, Muro S, Muzykantov VR. Advanced drug delivery systems that target the vascular endothelium. Mol. Interv. 2006; 6: 98–112.
14. Han XJ, Wei YF, Wan YY, Jiang LP, Zhang JF, Xin HB. Development of a novel liposomal nanodelivery system for bioluminescence imaging and targeted drug delivery in ErbB2-overexpressing metastatic ovarian carcinoma. Int. J. Mol. Med. 2014; 34: 1225–1232.
15. Barker AF, O’Donnell AE, Flume P, Thompson PJ, Ruzi JD, De Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir. Med. 2014; 2: 738–749.
16. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 2014; 189: 975–982.
17. Grimwood K, Bell SC, Chang AB. Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Rev. Anti-Infect. Ther. 2014; 12: 1277–1296.
18. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2012; 186: 657–665.
19. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculosis mycobacterial lung disease in US Medicare beneficiaries. Am. J. Respir. Crit. Care Med. 2012; 185: 881–886.
20. Rose SJ, Neville ME, Gupta R, Bermudez LE. Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection. PLoS ONE. 2014; 9: e108703.
21. Bermudez LE, Blanchard JD, Hauck L, Gonda I. Treatment of Mycobacterium avium subsp hominissuis (MAH) lung infection with liposome-encapsulated ciprofloxacin resulted in significant decrease in bacterial load in the lung. Am J Respir Crit Care Med. 2015; 191: A6293.
22. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. Bio-film penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemo. 2008; 61: 859–868.
23. Cipolla D, Gonda I, Chan HK. Liposomal Formulations for Inhalation. Ther. Deliv. 2013; 4: 1047–1072.
24. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN. Liposome Delivery of Ciprofloxacin against Intracellular Francisellatularensis Infection. J. Control. 2003; 92: 265–273.